Abstract
Human tumor in vivo cancer models raised in immunodeficient mice, the so-called patient-derived xenografts, are increasingly in use in preclinical development and evaluation of novel drug candidates including HDAC inhibitors. Here, we describe the techniques needed to generate novel patient-derived xenografts. The focus lies on vitally frozen tumor biopsies as starting material. First, the preparative steps on the animals, followed by the engraftment procedure itself, the tumor growth surveillance, the explantation procedure, and finally the handling of obtained xenograft tissues are described step by step. This technical description is completed by numerous tips and alternatives designed to allow for an easy adaptation and transfer to other laboratories.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Elias T, Gordian M, Singh N et al (2006) Why products fail in phase III. In Vivo 24:49–54
Sharma MR, Stadler WM, Ratain MJ (2011) Randomized phase II trials: a long-term investment with promising returns. J Natl Cancer Inst 103(14):1093–1100
Seymour L, Groshen S, Rosner GL et al (2015) Impact of the 2010 consensus recommendations of the clinical trial design task force of the NCI investigational drug steering committee. Clin Cancer Res 21(22):5057–5063
Siolas D, Hannon GJ (2013) Patient-derived tumor xenografts: transforming clinical samples into mouse models. Cancer Res 73(17):5315–5319. doi:10.1158/0008-5472.CAN-13-1069
Roth A, Singer T (2014) The application of 3D cell models to support drug safety assessment: opportunities & challenges. Adv Drug Deliv Rev 69–70:179–189
Decaudin D (2011) Primary human tumor xenografted models (‘tumorgrafts’) for good management of patients with cancer. Anticancer Drugs 22(9):827–841
Oberländer M, Linnebacher M, König A et al (2013) The “North German Tumor Bank of Colorectal Cancer”: status report after the first 2 years of support by the German Cancer Aid Foundation. Langenbecks Arch Surg 398(2):251–258
Maletzki C, Huehns M, Knapp P et al (2015) Functional characterization and drug response of freshly established patient-derived tumor models with CpG island methylator phenotype. PLoS One 10(11):e0143194
Mullins CS, Schneider B, Stockhammer F et al (2013) Establishment and characterization of primary glioblastoma cell lines from fresh and frozen material: a detailed comparison. PLoS One 8(8):e71070
Linnebacher M, Maletzki C, Ostwald C et al (2010) Cryopreservation of human colorectal carcinomas prior to xenografting. BMC Cancer 10:362
Wong JC, Tang G, Wu X et al (2012) Pharmacokinetic optimization of class-selective histone deacetylase inhibitors and identification of associated candidate predictive biomarkers of hepatocellular carcinoma tumor response. J Med Chem 55(20):8903–8925
Mariadason JM (2008) HDACs and HDAC inhibitors in colon cancer. Epigenetics 3(1):28–37
Vaish V, Khare T, Verma M et al (2015) Epigenetic therapy for colorectal cancer. Methods Mol Biol 1238:771–782. doi:10.1007/978-1-4939-1804-1_40
Bondarenko G, Ugolkov A, Rohan S et al (2015) Patient-derived tumor xenografts are susceptible to formation of human lymphocytic tumors. Neoplasia 17(9):735–741. doi:10.1016/j.neo.2015.09.004
Fujii E, Suzuki M, Matsubara K et al (2008) Establishment and characterization of in vivo human tumor models in the NOD/SCID/gamma(c)(null) mouse. Pathol Int 58(9):559–567. doi:10.1111/j.1440-1827.2008.02271
Prochazka M, Gaskins HR, Shultz LD et al (1992) The nonobese diabetic scid mouse: model for spontaneous thymomagenesis associated with immunodeficiency. Proc Natl Acad Sci U S A 89(8):3290–3294
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer Science+Business Media New York
About this protocol
Cite this protocol
Mullins, C.S., Bock, S., Krohn, M., Linnebacher, M. (2017). Generation of Xenotransplants from Human Cancer Biopsies to Assess Anti-cancer Activities of HDACi. In: Krämer, O. (eds) HDAC/HAT Function Assessment and Inhibitor Development. Methods in Molecular Biology, vol 1510. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-6527-4_16
Download citation
DOI: https://doi.org/10.1007/978-1-4939-6527-4_16
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-6525-0
Online ISBN: 978-1-4939-6527-4
eBook Packages: Springer Protocols